Skip to main content

Table 3 Cost-effectiveness results – base-case analysis

From: Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD

  Long-acting stimulant monotherapy GXR + long-acting stimulant Incrementala
Average QALYs 0.627 0.655 0.028
Patient-weeks with response 12.46 19.03 6.57
Drug costs, $CA 337 1,072 735
Medical costs, $CA 612 545 −67
Productivity losses, $CA 2,633 2,299 −334
Total cost, $CA
MoH perspective
949 1,617 668
Total cost, $CA
Societal perspective
3,582 3,915 334
Incremental cost/QALY, $CA
MoH perspective
   $CA23,720/ QALY
Incremental cost/QALY, $CA
Societal perspective
   $CA11,845/QALY
Incremental cost/patient-week with response, $CA
MoH perspective
   $CA102/responder
Incremental cost/patient-week with response, $CA
Societal perspective
   $CA51/responder
  1. aMay not sum to total because of rounding
  2. GXR guanfacine extended release, MoH Ministry of Health, QALY quality-adjusted life year